To evaluate and validate potential therapeutic platforms, we established a “3D organotypic-spheroid (OTS) model” of human chronic myelogenous leukemia (CML) with K562- target cells expressing cyan fluorescent protein (CFP) with the aim of reprogramming anergic NK cells in situ. Here, CFP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.